ZD-9379

ZD-9379
Names
	IUPAC name 7-Chloro-2-(4-methoxy-2-methylphenyl)-3,5-dihydropyridazino[4,5-b]quinoline-1,4,10-trione
Identifiers
3D model (JSmol)	Interactive image;
PubChem CID	9843028;
	InChI InChI=1S/C19H14ClN3O4/c1-9-7-11(27-2)4-6-14(9)23-19(26)15-16(18(25)22-23)21-13-8-10(20)3-5-12(13)17(15)24/h3-8H,1-2H3,(H,21,24)(H,22,25) Key: PSTDMIAVUUYOOQ-UHFFFAOYSA-N;
	SMILES CC1=C(C=CC(=C1)OC)N2C(=O)C3=C(C(=O)N2)NC4=C(C3=O)C=CC(=C4)Cl;
Properties
Chemical formula	C19H14ClN3O4
Molar mass	383.79 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ZD-9379 is an antagonist of the N-methyl-D-aspartate receptor. It possesses neuroprotective properties and could potentially be used for the treatment of certain strokes.

Mechanism of action

ZD-9379 works by antagonizing (blocking) the glycine site on the NMDA receptor,^[1]^[2] because both glycine (co-agonist) and an agonist at the main site are needed to activate the NMDA receptor, blocking the glycine binding site prevents the receptor from activating.

Potential use

In rats, ZD-9379 has been tested to help spreading depression and brain infarction, results have shown that treatment with ZD-9379 reduced the amount of spreading depressions and the volume of infarcts.^[3] Another study was also able to produce similar results.^[4]

References

^ "ZD 9379 | CAS 170142-20-8 | ZD9379 | Tocris Bioscience".
^ Danysz, Wojciech; Parsons, Chris G. (March 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists". Neurotoxicity Research. 4 (2): 119–126. doi:10.1080/10298420290015872. ISSN 1476-3524. PMID 12829411.
^ Tatlisumak, T.; Takano, K.; Meiler, M. R.; Fisher, M. (2000). "A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion". Acta Neurochirurgica. Supplement. 76: 331–333. doi:10.1007/978-3-7091-6346-7_68. ISSN 0065-1419. PMID 11450037.
^ Qiu, H.; Hedlund, L. W.; Gewalt, S. L.; Benveniste, H.; Bare, T. M.; Johnson, G. A. (1997). "Progression of a focal ischemic lesion in rat brain during treatment with a novel glycine/NMDA antagonist: an in vivo three-dimensional diffusion-weighted MR microscopy study". Journal of magnetic resonance imaging: JMRI. 7 (4): 739–744. doi:10.1002/jmri.1880070421. ISSN 1053-1807. PMID 9243396.

[1] "ZD 9379 | CAS 170142-20-8 | ZD9379 | Tocris Bioscience".

[2] Danysz, Wojciech; Parsons, Chris G. (March 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists". Neurotoxicity Research. 4 (2): 119–126. doi:10.1080/10298420290015872. ISSN 1476-3524. PMID 12829411.

[3] Tatlisumak, T.; Takano, K.; Meiler, M. R.; Fisher, M. (2000). "A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion". Acta Neurochirurgica. Supplement. 76: 331–333. doi:10.1007/978-3-7091-6346-7_68. ISSN 0065-1419. PMID 11450037.

[4] Qiu, H.; Hedlund, L. W.; Gewalt, S. L.; Benveniste, H.; Bare, T. M.; Johnson, G. A. (1997). "Progression of a focal ischemic lesion in rat brain during treatment with a novel glycine/NMDA antagonist: an in vivo three-dimensional diffusion-weighted MR microscopy study". Journal of magnetic resonance imaging: JMRI. 7 (4): 739–744. doi:10.1002/jmri.1880070421. ISSN 1053-1807. PMID 9243396.

[1]

[2]

[3]

[4]